Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02012192 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.

NCT NCT02012192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
Medical University Innsbruck
Phase
Phase 1/2
Overall status
Terminated
Start date
July 4, 2014
Completion date
December 4, 2017
Enrollment
133 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer